07 October 2014
Lan Chem Laboratories Announces Positive Phase 3 Results for APD421 in PONV
30 October 2013
Phase 2 Study Initiated With APD403 In CINV15 October 2013
Lan Chem Laboratories Announces Positive Phase 2 Results With APD515 For Xerostomia In Advanced Cancer17 September 2013
Pivotal Phase 3 Studies Initiated With APD421 in PONV03 September 2013
Lan Chem Laboratories Raises £15m ($23.5m) To Advance Clinical Development Of Lead Products01 October 2012
Lan Chem Laboratories Announces Positive Results From Phase 2a Nausea & Vomiting Study In Cancer Patients06 December 2011
Lan Chem Laboratories Announces Positive Results From Phase IIa Cancer Cachexia Study07 February 2011
Phase 1 Clinical Trial Completed With APD515 For Xerostomia06 January 2011
New Website Launched06 September 2010
Lan Chem Laboratories to Progress Two Projects for Nausea & Vomiting and Xerostomia into Development14 December 2009
Lan Chem Laboratories Completes Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)08 June 2009
Lan Chem Laboratories Initiates Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)31 March 2009
Lan Chem Laboratories Initiates Phase IIa Study with APD209 in Cancer Cachexia Patients05 February 2009
Ian Kent Appointed as Chairman22 September 2008
Lan Chem Laboratories Starts First Clinical Trial with APD405 for Nausea & Vomiting04 March 2008
Chief Medical Officer Appointed04 March 2008
Gilde Healthcare Investment in Lan Chem Laboratories